CRISPR/Cas9-Mediated Gene Knockout of ARID1A Promotes Primary Progesterone Resistance by Downregulating Progesterone Receptor B in Endometrial Cancer Cells
Authors:
Open Access
- 23 September 2019
- journal article
- research article
- Published by Tech Science Press in Oncology Research
- Vol. 27 (9) , 1051-1060
Abstract
Medroxyprogesterone (MPA) is used for the conservative treatment of endometrial cancer. Unfortunately, progesterone resistance seriously affects its therapeutic effect. The purpose of the current study was to investigate the influence of deletion of AT-rich interactive domain 1A (ARID1A) in progesterone resistance in Ishikawa cells. Ablation of ARID1A was conducted through the CRISPR/Cas9 technology. Acquired progesterone-resistant Ishikawa (Ishikawa-PR) cells were generated by chronic exposure of Ishikawa cells to MPA. The sensitivity of the parental Ishikawa, Ishikawa-PR, and ARID1A-deficient cells to MPA and/or LY294002 was determined using the Cell Counting Kit-8 (CCK-8) assay and flow cytometry analysis. In addition, Western blot analysis and reverse transcription-polymerase chain reaction was performed to evaluate the mRNA and protein expression levels of ARID1A, progesterone receptor B (PRB), and P-AKT. Both Ishikawa-PR and ARID1A knockout cells showed insensitivity to MPA, downregulation of PRB, and hyperphosphorylation of AKT compared to the parental Ishikawa cells. Pretreatment with LY294002 significantly enhanced the ability of MPA to suppress proliferation and to induce apoptosis in the parental and Ishikawa-PR cells via the inhibition of AKT activation and upregulation of PRB transcriptional activity. However, the PRB transcriptional activity and insensitivity to MPA were irreversible by LY294002 in ARID1A-deficient cells. Ablation of ARID1A is associated with low PRB expression, which serves an important role in primary progesterone resistance. Akt inhibition cannot rescue PRB or sensitize to MPA in ARID1A knockout cells. These findings suggest that ARID1A may act as a reliable biomarker to predict the response for the combination of AKT inhibitor and MPA treatment.Keywords
This publication has 25 references indexed in Scilit:
- ARID1A gene mutation in ovarian and endometrial cancers (Review)Oncology Reports, 2015
- ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsCancer Discovery, 2015
- Progestins in the Fertility-Sparing Treatment and Retreatment of Patients With Primary and Recurrent Endometrial CancerThe Oncologist, 2015
- Role of nuclear progesterone receptor isoforms in uterine pathophysiologyHuman Reproduction Update, 2014
- LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapyMolecular Medicine Reports, 2014
- Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetateOncology Letters, 2012
- Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to ProgestinPLOS ONE, 2012
- Target genes of the largest human SWI/SNF complex subunit control cell growthBiochemical Journal, 2011
- Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancerCancer Science, 2011
- Role of Progesterone in Endometrial CancerSeminars in Reproductive Medicine, 2010